Actively Recruiting
Evaluation of Brentuximab Vedotin and Bendamustine Combination Therapy for Relapsed or Resistant Follicular Lymphoma
Led by University of California, Davis · Updated on 2026-06-29
23
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of brentuximab vedotin and bendamustine for treating patients with follicular lymphoma that has returned or does not respond to previous treatments. Brentuximab vedotin is a targeted monoclonal antibody that attaches to CD30 positive cancer cells and delivers a toxic agent to kill them, while bendamustine is chemotherapy that stops cancer cells from growing or spreading. This phase II trial aims to assess the safety and effectiveness of this drug combination in patients with relapsed or refractory CD30-positive follicular lymphoma. Participants receive brentuximab vedotin intravenously over 30 minutes on day 1 and bendamustine intravenously over 60 minutes on days 1 and 2 of each 21-day cycle, repeated for 6 cycles unless the disease progresses or toxicity occurs. Those who respond and tolerate the combination may continue with brentuximab vedotin alone every 21 days for up to 10 additional cycles. After finishing treatment, participants have a 30-day follow-up and then are monitored every 3 months for 2 years. During the study, patients undergo disease assessments using CT or PET scans and are monitored for response, progression-free survival, overall survival, and side effects. Researchers collect data on complete response rates and best overall responses up to 2 years. Safety and tolerability are evaluated throughout, with follow-up visits scheduled to monitor health status and disease progression after treatment ends. Participation duration can last up to 2 years including treatment and follow-up.
CONDITIONS
Brief Title
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here